• Minicabecera2

Cell Therapy Programs

HC016

HC016 cells are adipose tissue derived mesenchymal stem cells that have been pre-conditioned following a proprietary protocol to increase their resistance and survival in cytotoxic environments and enhance their anti-inflammatory and tissue protection properties.

HC016 cells are clinical candidates for the treatment of diseases mediated by oxidative stress such as Acute Spinal Cord Injury (Neurosave), Acute Lung Disease (ALD) and Critical Limb Ischemia (LIS).

HC016 in Neuroprotection & Repair

Allogeneic, neuro-protective cell therapy based on a suspension of HC016 cells for the early stage treatment of traumatic injuries to the spinal cord.

HC016 cells regulate the inflammatory process in the injury site by releasing specific enzymes and growth factors, limiting the damage to the healthy tissue that occurs following trauma. Efficacy of HC016 cells is boosted due to their enhanced resistance to the cytotoxic environment in the injury site.

An "in vivo" PoC study has been successfully completed, including a safety "in vivo" study.

Clinical Phase I/II scheduled for 2016.

License & co-development agreement with Grupo Ferrer.

HC016 in Acute Lung Disease

Histocell has developed successfully "in vivo" proof of concept study for Acute Lung Disease.

HC016 in Critical Limb Ischemia

Histocell has designed proof of concept studies involving HC016 cells in Critical Limb Ischemia in collaboration with leading international institutions.

 

Bone regeneration

Innovative autologous cell therapy product for osseous regeneration based on a combination of adipose tissue derived mesenchymal stem cells and a novel, patented bone substitute with optimal bone remodeling properties.

The regenerative properties of cells are enhanced by the use of an engineered, bone-like scaffold made of a biocompatible calcium phosphate derivate. The scaffold’s macro/micro porous structure enables cells to attach and grow both on its surface and internally, ensures an adequate revascularization of the newly formed tissue and induces a guided regeneration process that allows for an optimal integration of the new tissue with the surrounding bone.

Clinical Phase II study for Pseudoarthrosis started in 2015.

First patient has already been included in the study.

License & co-development agreement with Salvat Biotech.